Development of Monoclonal Antibody PMab-269 Against California Sea Lion Podoplanin.


Journal

Monoclonal antibodies in immunodiagnosis and immunotherapy
ISSN: 2167-9436
Titre abrégé: Monoclon Antib Immunodiagn Immunother
Pays: United States
ID NLM: 101590955

Informations de publication

Date de publication:
Jun 2021
Historique:
pubmed: 28 5 2021
medline: 4 1 2022
entrez: 27 5 2021
Statut: ppublish

Résumé

The development of protein-specific antibodies is essential for understanding a wide variety of biological phenomena. Parasitic and viral infections and cancers are known to occur within California sea lion (

Identifiants

pubmed: 34042540
doi: 10.1089/mab.2021.0011
doi:

Substances chimiques

Antibodies, Monoclonal 0
Membrane Glycoproteins 0
PDPN protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

124-133

Auteurs

Tomohiro Tanaka (T)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.

Teizo Asano (T)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.

Masato Sano (M)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.

Junko Takei (J)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.
Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Bunkyo-ku, Japan.

Hideki Hosono (H)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.

Ren Nanamiya (R)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.

Takuro Nakamura (T)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.

Miyuki Yanaka (M)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.

Hiroyuki Harada (H)

Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Bunkyo-ku, Japan.

Masato Fukui (M)

Zenoaq Resource Co., Ltd., Koriyama, Japan.

Hiroyoshi Suzuki (H)

Department of Pathology and Laboratory Medicine, Sendai Medical Center, Sendai, Japan.

Kazuyuki Uchida (K)

Laboratories of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Bunkyo-ku, Japan.

Takayuki Nakagawa (T)

Laboratories of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Bunkyo-ku, Japan.

Yukinari Kato (Y)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.
New Industry Creation Hatchery Center, Tohoku University, Sendai, Japan.

Mika K Kaneko (MK)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH